Penserra Capital Management LLC Bluebird Bio, Inc. Transaction History

Penserra Capital Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$2.94 - $5.23 $7,973 - $14,183	2,712 Added 24.62%	13,728 $56,000
Q1 2022 May 13, 2022	BUY	$4.07 - $10.6 $44,835 - $116,769	11,016 New	11,016 $53,000
Q4 2021 Feb 15, 2022	SELL	$8.96 - $16.31 $13,843 - $25,198	-1,545 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$11.24 - $21.0 $112 - $210	10 Added 0.65%	1,545 $29,000
Q2 2021 Aug 12, 2021	BUY	$18.04 - $22.09 $360 - $441	20 Added 1.32%	1,535 $49,000
Q1 2021 May 13, 2021	SELL	$16.59 - $33.89 $331 - $677	-20 Reduced 1.3%	1,515 $45,000
Q4 2020 Feb 12, 2021	BUY	$27.5 - $37.92 $26,647 - $36,744	969 Added 171.2%	1,535 $66,000
Q3 2020 Nov 13, 2020	SELL	$34.44 - $43.75 $40,811 - $51,843	-1,185 Reduced 67.68%	566 $30,000
Q2 2020 Aug 14, 2020	BUY	$27.12 - $45.97 $47,487 - $80,493	1,751 New	1,751 $106,000

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $28.5M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.